• For US Healthcare Professionals

    Visit Patient Site
    Request a Representative or SamplesPrescribing InformationSee Schizophrenia Data
  • Request a Representative
    Order Samples

    • For US Healthcare Professionals

    See Schizophrenia DataVisit Patient Site

    Bipolar I depression
    bipolar II depression
    approved for both

    CAPLYTA is an FDA-approved treatment option for bipolar I and bipolar II depression in adults as monotherapy and adjunctive therapy with lithium or valproate.1

    Efficacy across multiple measures

    Bipolar IndicationsPrimary Efficacy
    Disease SeverityQuality of Life

    Consistent Safety Profile Across Trials

    Most Common Adverse ReactionsEPS and Akathisia
    Weight and Metabolic Effects

    Savings Offer and Resources

    Order SamplesSavings Card
    Pharmacy Callback GuidePrior Authorization Form

    Attend a CAPLYTA speaker program

    Watch a peer-led presentation on the CAPLYTA clinical profile

    Sign up

    Help your patients Let in the LYTE

    Read Transcript

    Help your patients Let in the LYTE

    Read Transcript

    Reference: 1. CAPLYTA prescribing information.

  • Terms of Use
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • Disclosures
  • Sitemap
  • AdChoices Opt-out

    • CAPLYTA is a registered trademark, and LYTE THEIR WAY and LET IN THE LYTE are trademarks of Intra-Cellular Therapies, Inc.

    All other trademarks and registered trademarks are the property of their respective owners.

    © 2023 Intra-Cellular Therapies, Inc. All rights reserved. US-CAP-2200128 05/22